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Abstract
Background: Unrecognized myocardial infarction (UMI) is known to constitute a substantial portion of potentially lethal
coronary heart disease. However, the diagnosis of UMI is based on the appearance of incidental Q-waves on 12-lead
electrocardiography. Thus, the syndrome of non-Q-wave UMI has not been investigated. Delayed-enhancement
cardiovascular magnetic resonance (DE-CMR) can identify MI, even when small, subendocardial, or without associated Q-
waves. The aim of this study was to investigate the prevalence and prognosis associated with non-Q-wave UMI identified by
DE-CMR.
Methods and Findings: We conducted a prospective study of 185 patients with suspected coronary disease and without
history of clinical myocardial infarction who were scheduled for invasive coronary angiography. Q-wave UMI was
determined by electrocardiography (Minnesota Code). Non-Q-wave UMI was identified by DE-CMR in the absence of
electrocardiographic Q-waves. Patients were followed to determine the prognostic significance of non-Q-wave UMI. The
primary endpoint was all-cause mortality. The prevalence of non-Q-wave UMI was 27% (50/185), compared with 8% (15/185)
for Q-wave UMI. Patients with non-Q-wave UMI were older, were more likely to have diabetes, and had higher Framingham
risk than those without MI, but were similar to those with Q-wave UMI. Infarct size in non-Q-wave UMI was modest (8%67%
of left ventricular mass), and left ventricular ejection fraction (LVEF) by cine-CMR was usually preserved (52%618%). The
prevalence of non-Q-wave UMI increased with the extent and severity of coronary disease on angiography (p,0.0001 for
both). Over 2.2 y (interquartile range 1.8–2.7), 16 deaths occurred: 13 in non-Q-wave UMI patients (26%), one in Q-wave UMI
(7%), and two in patients without MI (2%). Multivariable analysis including New York Heart Association class and LVEF
demonstrated that non-Q-wave UMI was an independent predictor of all-cause mortality (hazard ratio [HR] 11.4, 95%
confidence interval [CI] 2.5–51.1) and cardiac mortality (HR 17.4, 95% CI 2.2–137.4).
Conclusions: In patients with suspected coronary disease, the prevalence of non-Q-wave UMI is more than 3-fold higher
than Q-wave UMI. The presence of non-Q-wave UMI predicts subsequent mortality, and is incremental to LVEF.
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In patients with coronary artery disease (CAD), the diagnosis of
myocardial infarction (MI) directs clinical management and affects
prognosis. However, MI can be associated with atypical, minimal,
or no symptoms and thus may occur ‘‘unrecognized’’ by the
patients themselves and their physicians. Despite this unremark-
able presentation, unrecognized MI (UMI) adversely affects
prognosis with mortality rates that are similar to myocardial
infarctions that are recognized clinically [1–3].
Large population surveys have shown that as many as 40%–
60% of all MIs are unrecognized [1–6]. In these studies, serial 12-
lead electrocardiograms (ECGs) were performed annually or
biennially and the diagnosis of UMI was made on the basis of new
Q-waves on successive ECGs without the occurrence of a clinically
evident MI. Therefore, by definition, patients with non-Q-wave
infarcts were not identified. Accordingly, the syndrome of non-Q-
wave UMI has not been examined, and the prevalence and
prognostic significance of this syndrome are unknown.
Delayed-enhancement cardiovascular magnetic resonance (DE-
CMR) is a relatively recent technique that can identify MI, even
when small, subendocardial, or without associated Q-waves [7].
Initial studies suggest that DE-CMR for the assessment of MI is
reproducible [8] and provides results superior to radionuclide
imaging in patients with small infarcts [9,10].
The purpose of the current study was to determine the
prevalence of non-Q-wave UMI—identified by DE-CMR—in
comparison to Q-wave UMI in patients with suspected CAD who
had no history of MI. We prospectively enrolled patients
scheduled for invasive coronary angiography in order to directly
relate the presence of UMI to the extent and severity of coronary
atherosclerosis. Patients were then followed for over 2 y to
determine whether the presence of non-Q-wave UMI portends
increased mortality.
Methods
Population
Patients with suspected CAD (i.e., not already known to have
CAD) who were scheduled for elective X-ray coronary angiogra-
phy were prospectively recruited. The decision to perform
coronary angiography had been made prior to study recruitment.
Prior MI was defined using the criteria of the World Health
Organization (WHO criteria: [1] evolving diagnostic ECG, or [2]
diagnostic ECG and abnormal enzymes, or [3] prolonged cardiac
pain and abnormal enzymes). Patients with MI verified by the
medical record were excluded. Patients with only Q-waves on 12-
lead ECG in the absence of clinical MI were not excluded, since
one of the main aims of the study was to compare the prevalence
of non-Q-wave to that of Q-wave UMI.
Additional exclusion criteria were: (1) history of percutaneous
coronary intervention (PCI) or coronary artery bypass grafting
(CABG), since small infarcts are common in the setting of successful
revascularization procedures [11] and we wished to exclude infarcts
from iatrogenic causes; (2) nonischemic myocardial disorders such as
hypertrophic or infiltrative cardiomyopathy, and myocarditis, since
these disorders frequently cause myocardial necrosis and/or scarring
[12–14]; (3) any serious intercurrent illness such as uncured
malignancy that could shorten survival to less than 2 y; or (4)
contraindication to CMR (e.g., pacemaker). All patients were
enrolled before the recent Federal Drug Administration alerts
regarding the rare occurrence of nephrogenic systemic fibrosis
associated with gadolinium administration [15]. Four patients had
end-stage renal disease and were receiving dialysis therapy at the
time of enrollment. None of the study participants developed
nephrogenic systemic fibrosis during the follow-up period.
Patients were prospectively enrolled from two sites, Northwest-
ern Memorial Hospital (n=100) between January 1998 through
October 2001 and Duke University Medical Center (n=85)
between December 2002 and January 2004. The gap in study
enrollment occurred during relocation of some personnel to the
latter institution. Institutional review board approval was obtained
at both sites. Potential participants were identified prospectively
from the cardiac catheterization laboratory schedule and subse-
quently contacted by the investigators. Those who fulfilled the
study criteria were asked to participate, and consecutive patients
who signed consent were included in the study. Importantly, all
CMR studies were performed only for research purposes and were
not clinically ordered scans. There were no significant incidental
findings, and CMR results were not used to guide clinical decision-
making (e.g., coronary revascularization).
Protocol
Baseline procedures. All patients were interviewed using a
standardized questionnaire to obtain a complete medical history,
including responses to the Rose chest pain questionnaire [16].
Participants were considered to have hypertension, diabetes
mellitus, or hypercholesterolemia if they had a documented
diagnosis by a physician, supportive laboratory data, or were
taking medications for these conditions. Coronary heart disease
risk was estimated by the Framingham prediction algorithm [17].
Standard 12-lead ECGs were obtained in all patients. In the
majority of patients, CMR was performed immediately prior to
angiography on the same day (interquartile range [IQR] 0–2 d;
within 30 d in all patients).
Follow-up. Clinical follow-up was obtained annually via
telephone interview with the patient or immediate family
member, the patient’s physician, hospital records, and death
certificates. Data regarding subsequent revascularization, MI, and
death were recorded. The prespecified primary endpoint was all-
cause mortality [18]. The secondary endpoint was cardiac
mortality. The median follow-up time at Northwestern was
similar to that at Duke (2.2 versus 2.4 y, respectively, p=0.22).
All participants (survivors) had a minimum of 1 y of follow-up.
CMR
All images were acquired on a clinical 1.5T scanner (Siemens
Sonata) using a phased array receiver coil during repeated breath-
holds as described previously [19]. Briefly, cine-CMR images were
acquired in multiple short- and long-axis views using a steady-state
free procession sequence. Short-axis views were obtained every
1 cm to cover the entire left ventricle (6 mm thickness, 4 mm gap).
A gadolinium-based contrast agent (gadoteridol or gadoverse-
tamide) was administered intravenously (0.15 mmol/kg), and DE-
CMR images were acquired in the same views used for cine-CMR
10–15 min later. DE-CMR images were acquired using a
segmented inversion-recovery sequence with inversion time
adjusted to null normal myocardium; typical in-plane resolution
was 1.961.4 mm with a slice thickness of 6.0 mm [20]. No patient
was excluded on the basis of CMR image quality.
Analysis
Cine-CMR, DE-CMR, ECG, and coronary angiography were
interpreted by a consensus of two observers who were masked to
patient identity and clinical history in separate reading sessions.
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volumes were quantitatively measured via end-diastolic and end-
systolic endocardial contours from the stack of short-axis cine
images [19].
DE-CMR. The presence and location of hyperenhanced
tissue, which was assumed to represent scarred myocardium
[19,21], was determined by visual inspection using the AHA 17-
segment model [22]. Regional enhancement was scored according
to the spatial extent of hyperenhanced tissue within each segment
(0=no hyperenhancement; 1=1%–25% hyperenhanced;
2=26%–50%; 3=51%–75%; and 4=76%–100%) [7]. On a
per patient basis, infarction was considered transmural if one or
more segments had a score of 4 (76%–100%). Additionally, the
pattern of hyperenhancement was classified as either CAD-type or
non-CAD-type as described previously [23–25]. In brief, since
ischemic injury progresses as a ‘‘wavefront’’ from the
subendocardium to the epicardium [26], hyperenhancement
involving the subendocardium was considered CAD-type.
Conversely, hyperenhancement patterns that spared the
subendocardium and instead were limited to the middle or
epicardial portion of the left ventricular (LV) wall were considered
non-CAD-type. An exception was in the setting of subendocardial
enhancement diffusely throughout the entire LV, which can occur
in certain nonischemic cardiomyopathies (e.g., cardiac
amyloidosis). This pattern was classified as non-CAD-type.
Although our primary focus was to identify the presence of
UMI, infarct size was also measured by planimetry from the stack
of short-axis DE-CMR images [27]. The infarct borders were
determined visually in our CMR core laboratory. Interobserver
agreement for infarct size, routinely tested as part of our core
laboratory services using Bland-Altman analysis, demonstrated a
bias of 1.0% with a standard deviation (SD) of the difference of
2.6%. Additionally, in a random sample of 15% of the study
population, infarct size was measured twice (6 mo apart) to
determine intraobserver agreement. Analysis of this subset
demonstrated a bias of 20.1% with a standard deviation of the
difference of 0.8%. A fixed cutoff of 2 SD above the mean signal
intensity of normal myocardium was not used to define the
infarcted region because this approach does not account for partial
volume effects [27].
ECG. The presence of Q-waves was determined on the basis
of Minnesota codes 1-1-1 to 1-2-7 [28]. Electrocardiograms were
also scored for the presence of complete left bundle branch block
(7-1-1).
Coronary angiography. Obstructive CAD was defined as
$50% narrowing of the luminal diameter of at least one major
epicardial artery [29]. Luminal narrowing was estimated visually
by the consensus of two experienced readers.
Definitions of Q-wave and non-Q-wave UMI. Q-wave
UMI was defined solely by the presence of major Q-waves on
electrocardiography to allow a direct comparison of the results of
the current study to published data [2–4]. Non-Q-wave UMI was
defined by the presence of CAD-type hyperenhancement on DE-
CMR in those patients lacking Q-waves. Patients with non-CAD-
type hyperenhancement and those without hyperenhancement
were both classified as having ‘‘no MI.’’ Since these two groups
may have different prognoses, survival in the ‘‘no MI’’ group was
also assessed after excluding patients with non-CAD-type
hyperenhancement.
Statistical Analysis
Continuous data are presented as mean6SD or, in cases where
the distribution is not normal, as median and IQR. Two-sample t-
tests were used to compare mean values of continuous data
between two groups. Comparisons between discrete data were
made using Chi-square tests. Differences in means between more
than two groups were assessed using analysis of variance; the
Bonferroni method of adjustment was used in making multiple
pairwise comparisons. The relationship between angiographic
parameters and the frequency of Q-wave and non-Q-wave UMI
was evaluated using the Chi-square test for trend.
In order to identify the clinical characteristics associated with
non-Q-wave UMI, univariable and multivariable logistic regres-
sion analyses were performed in the remaining cohort of patients
after excluding those with Q-wave UMI. In the same group, Cox
regression analysis was performed to assess the effect of non-Q-
wave UMI on both all-cause and cardiac mortality. Initially, the
univariable predictors were identified, then only variables with p-
values below 0.10 were considered candidate predictors of
mortality in the multivariable model to reduce the possibility of
overfitting. As part of separate analyses, revascularization (CABG
or PCI) during the follow-up period and enrollment site were
included as covariates in order to account for their effects on
survival. All statistical tests were two-tailed and p,0.05 was
regarded as significant.
Results
Clinical Characteristics and Prevalence of Unrecognized
Non-Q-wave MI
A total of 185 patients were enrolled. All successfully underwent
CMR. Table 1 demonstrates the clinical characteristics of the
population. Overall, the mean age of the group was 60.4 y (range
25–86 y). Left ventricular function was usually preserved (LVEF
59%618%). The majority had chest pain (62%) and/or dyspnea
(30%). In 158 patients (85%), the indication for coronary
angiography was a positive or equivocal radionuclide, echocardi-
ography, or treadmill stress test. In the remaining 15%, the
primary physician elected to proceed directly to coronary
angiography based on typical symptoms alone.
Overall, the prevalence of non-Q-wave UMI was 27% (50/185)
and 3.3-fold higher than that of Q-wave UMI (8%, 15/185).
Patients with non-Q-wave UMI were older, had a higher
prevalence of diabetes, had a higher Framingham risk, and had
lower LVEFs than those without MI (Table 1).
Infarct Size and Location
In patients with non-Q-wave UMI, infarct size varied over a
wide range, but overall was relatively modest (8%67% of LV;
range 1%–22%). Patients with Q-wave UMI also had a wide
range of infarct sizes (0%–27%), including three without evidence
of infarction by DE-CMR. All three had normal coronary
angiograms, suggesting that the Q-waves in these three were false
positive for MI. Mean infarct size excluding these three patients
was 14%69% of LV, and larger than for non-Q-wave UMI
patients (p=0.02). Additionally, patients with non-Q-wave UMI
were less likely to have transmural infarcts than those with Q-wave
UMI (18% versus 58%, respectively, p=0.002). In patients with
non-Q-wave UMI, infarct location by DE-CMR was distributed as
follows: 40% left anterior descending coronary artery (LAD)
perfusion territory, 47% right coronary artery (RCA), and 13%
left circumflex coronary artery (LCx). The distribution was similar
(p=0.74) in those with Q-wave UMI (44% LAD, 50% RCA, 6%
LCx).
Ten patients (20%) with non-Q-wave and four (28%) with Q-
wave UMI had two infarcts (i.e., separate infarcts in different
coronary artery territories). Typical images of patients with non-
Q-wave UMI are shown in Figure 1 (patients A–C). In nine
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non-CAD-type pattern was observed, the most common of which
was midwall striae in the interventricular septum (n=6, Figure 1,
patient D).
Correlation with Coronary Artery Disease
Overall, coronary angiography revealed obstructive CAD in 61%
(112/185) of the population. In patients with non-Q-wave UMI, with
Q-wave UMI, and without MI, CAD was present in 96% (48/50),
73% (11/15), and 44% (53/120), respectively. Figure 2 shows the
prevalence of UMI stratified by the angiographic extent and severity
o fC A D .B o t ht h ep r e v a l e n c eo fn o n - Q - w a v ea n dQ - w a v eU M I
increased with CAD extent (p,0.0001 and p,0.001 for trend,
respectively) and severity (p,0.0001 and p,0.001 for trend,
respectively). However, the relationship was steeper for non-Q-wave
UMI, with the prevalence reaching 53% in patients with triple vessel
disease (versus 15% Q-wave UMI prevalence) and 64% in those
with maximal stenosis over 90% (versus 17% Q-wave UMI
prevalence).
Clinical Predictors of Non-Q-Wave UMI
Besides the correlation with angiographic CAD extent and
severity, the following were significant univariable predictors of
non-Q-wave UMI: age, diabetes, NHYA class, Framingham risk,
and LVEF (Table 2). Multivariable analysis demonstrated that age
(p=0.01), diabetes (p=0.03), and LVEF (p=0.0003) remained
independent clinical predictors. The risk of non-Q-wave UMI
increased by 1.6-fold, 2.4-fold, and 1.4-fold for every 10-y increase
Table 1. Clinical characteristics.
Characteristic All Patients (n=185)
Q-wave UMI
(n=15)
Non-Q-wave UMI
(n=50) No MI (n=120) p-Value
Age 60.4611.2 58.5610.7 64.3611.4 59.1611.0 0.02
a
Male 66% 73% 74% 63% 0.30
CAD risk factors
Hypertension 123 (66%) 12(80%) 35 (70%) 76 (63%) 0.36
Hypercholesterolemia 90 (49%) 7 (47%) 23 (46%) 60 (50%) 0.88
Cigarette smoking 53 (29%) 8 (53%) 16 (32%) 29 (24%) 0.052
Diabetes mellitus 57 (31%) 5 (33%) 22 (44%) 30 (25%) 0.049
a
Family history of CAD 66 (36%) 2 (13%) 16 (30%) 49 (41%) 0.07
Number of risk factors 2.161.1 2.361.3 2.261.1 2.061.1 0.49
Symptoms
Chest pain
b 0.74
Typical angina 57 (31%) 4 (27%) 16 (32%) 37 (31%)
Atypical angina 57 (31%) 6 (43%) 12 (24%) 39 (33%)
None 71 (38%) 5 (36%) 22 (43%) 44 (37%)
Dyspnea 56 (30%) 4 (27%) 19 (38%) 33 (28%) 0.38
NYHA class 1.460.8 1.561.0 1.761.0 1.360.7 0.051
Medications
Aspirin 109 (59%) 13 (87%) 32(64%) 64 (53%) 0.03
Beta blocker 74 (40%) 7 (47%) 21 (42%) 46 (38%) 0.78
ACE-I 86 (46%) 7 (47%) 27 (54%) 52 (43%) 0.45
Statin 65 (35%) 2 (13%) 19 (38%) 44 (37%) 0.18
Nitrate 29 (16%) 6 (40%) 13 (26%) 10 (8%) 0.0004
a
Calcium channel blocker 38 (21%) 5 (33%) 16 (32%) 17 (14%) 0.01
a
Framingham risk score
c 16.2612.3 20.1613.6 22.5615.3 13.5610.0 0.0006
a
12-lead ECG
Q-waves
d 15 (8%) 15 (100%) — — —
Left bundle branch block
e 10 (5%) — 4 (8%) 6 (5%) —
Cine CMR
LVEF 59618 48620 52618 63617 ,0.0001
a
End diastolic volume, ml 114647 104636 106645 118648 0.23
End systolic volume, ml 50641 56635 54637 48643 0.57
ap,0.05 for pairwise comparison between non-Q-wave UMI and no MI.
bAngina defined by Rose Chest Pain Questionnaire. The p value pertains to the comparison in the distribution of patients according to chest pain.
cCalculated in the 140 patients who had all relevant blood tests.
dMinnesota codes 1-1-1 to 1-2-7.
eMinnesota codes 7-1-1.
ACE-I, angiotensin converting enzyme inhibitor.
doi:10.1371/journal.pmed.1000057.t001
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point decrease in LVEF, respectively.
Survival
The median follow-up time was 2.2 y (IQR 1.8–2.7). No patient
was lost to follow-up. During the follow-up period, 16 patients
died, resulting in an overall mortality rate of 3.8% per year. Three
patients experienced nonfatal MI during the follow-up period, and
subsequently died 3, 4, and 28 mo later. Among patients with non-
Q-wave UMI, there were 13 deaths (10.8% per year), including 10
cardiac, one noncardiac, and two from unknown causes. In
patients with Q-wave UMI, there was one death (2.7% per year),
which was cardiac. In patients without MI, there were two deaths
(0.8%per year), including one cardiac and one noncardiac. Among
the nine with non-CAD-type hyperenhancement, no deaths
occurred.
Patients with non-Q-wave UMI (n=50) had reduced overall
and cardiac survival compared to patients without MI (n=120), as
demonstrated by the Kaplan-Meier curves in Figure 3 (p,0.0001
for both). Given that the Q-wave UMI group consisted of only 15
Figure 1. Typical DE-CMR images. Short and long axis views of DE-CMR images from four patients are shown. Patients A–C demonstrate
hyperenhancement (red arrows) consistent with prior myocardial infarction. None had Q-waves on electrocardiography, and all three were classified
as having non-Q-wave UMI. Of note, Patient C has evidence of two distinct infarcts. Patient D has hyperenhancement (blue arrows) involving the
midwall of the interventricular septum, sparing the subendocardium. This pattern is not consistent with prior myocardial infarction, and this patient
was categorized in the ‘‘no MI’’ group. See text for further details.
doi:10.1371/journal.pmed.1000057.g001
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Q-waveUMIorthe no-MI group.Amongthe clinical characteristics,
significant univariable predictors of all-cause mortality were New
YorkHeartAssociation(NYHA)class,LVEF,andnon-Q-wave UMI
(Table 3). However, in multivariable analysis—in which only
candidate variables with p,0.10 from the univariable analysis were
considered (NYHA class, LVEF, non-Q-wave UMI, and revascular-
ization during the follow-up period)—LVEF and non-Q-wave UMI
were independent predictors. We note that 35% (64/185) of the
entire study population underwent revascularization during the
follow-up period (CABG, 46; PCI, 18), and specifically in the two
comparison groups, 66% (33/50) of patients with non-Q-wave UMI
and 20% (24/120) without MI underwent revascularization. After
adjustment for revascularization, multivariable analysis demonstrated
that LVEF and the presence of non-Q-wave UMI remained as
independent predictors of mortality. These two variables were again
identified as the only independent predictors after adjustment for
enrollment site. Likewise, when only fatal cardiac events were
considered, LVEF and non-Q-wave UMI were once again identified
as independent predictors of mortality (Table 4).
Discussion
This investigation is, to our knowledge, the first to systematically
characterize the syndrome of unrecognized non-Q-wave myocar-
Figure 2. Prevalence of UMI stratified by angiographic extent
and severity of coronary artery disease. The prevalence of non-Q-
wave and Q-wave UMI increased with both the extent and severity of
CAD. See text for further details. CAD=coronary artery disease;
UMI=unrecognized myocardial infarction; 1V=single vessel; 2V=dou-
ble vessel; 3V=triple vessel.
doi:10.1371/journal.pmed.1000057.g002
Table 2. Clinical predictors of non-Q-wave UMI.
Characteristic Univariable Multivariable
Odds Ratio
a (95% CI) p-Value Odds Ratio
a (95% CI) p-Value
Age 1.05 (1.01–1.08) 0.007 1.05 (1.01–1.08) 0.01
Male 1.71 (0.82–3.55) 0.15
CAD risk factors
Hypertension 1.35 (0.66–2.75) 0.41
Hypercholesterolemia 0.85 (0.44–1.65) 0.85
Cigarette smoking 1.48 (0.71–3.05) 0.30
Diabetes mellitus 2.36 (1.18–4.72) 0.02 2.40 (1.12–5.11) 0.03
Family history of CAD 0.62 (0.31–1.26) 0.19
Number of risk factors 1.18 (0.86–1.62) 0.30
Symptoms
Chest pain
b
Typical angina 1.06 (0.52–2.15) 0.88
Atypical angina 0.66 (0.31–1.39) 0.27
Any 0.74 (0.38–1.44) 0.37
Dyspnea 1.62 (0.80–3.25) 0.18
NYHA class 1.64 (1.09–2.45) 0.02
Framingham risk score
c 1.06 (1.02–1.09) 0.0009
12-lead ECG
Left bundle branch block
d 1.65 (0.45–6.13) 0.45
Cine CMR
LVEF 0.97 (0.95–0.99) 0.0008 0.96 (0.94–0.98) 0.0003
End diastolic volume 0.99 (0.99–1.00) 0.15
End systolic volume 1.00 (1.00–1.01) 0.39
aThe odds ratios are associated with a single unit increase for all of the continuous variables.
bAngina defined by Rose Chest Pain Questionnaire.
cCalculated in the 130 patients who had all relevant blood tests.
dMinnesota codes 7-1-1.
doi:10.1371/journal.pmed.1000057.t002
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cohort without known prior MI referred for coronary angiogra-
phy, one-third (62/185) had evidence of unrecognized MI by DE-
CMR, among whom 80% (50/62) had no Q-waves. The presence
of unrecognized non-Q-wave MI predicted a 11-fold higher risk of
death and a 17-fold higher risk of cardiac death than those without
MI.
It has been estimated that 190,000 patients in the United States
and perhaps as many as 300,000 in Europe suffer from silent MI
annually [30,31]. Since these estimates reflect only patients with
electrocardiographic Q-waves, the data from the current study
suggest that when those with non-Q-wave UMI are added, the
actual incidence may be more than 3-fold higher. Although the
magnitude of this discrepancy may be surprising, the concept that
electrocardiography underestimates the incidence of UMI is not—
since even among patients with clinically overt MI, Q-waves are
more frequently absent than present [32]. Additionally, even if Q-
waves are present initially, up to one-third may subsequently
disappear during infarct healing [33].
The diagnosis of non-Q-wave UMI is difficult because, by
definition, these patients either do not present during the acute
phase of infarction or, even if they do present, MI is not suspected
and cardiac biomarkers, such as troponins, are not drawn. Thus,
even if some patients later undergo cardiac assessment, the infarct
will be chronic. Accordingly, troponin levels will be normal, and
the ECG will be nondiagnostic. In these circumstances, noninva-
sive imaging may be helpful.
Although radionuclide perfusion imaging and echocardiogra-
phy have proven utility for the assessment of myocardial viability
in patients with chronic CAD and extensive LV dysfunction
[34,35], viability testing is typically not performed in the setting of
normal or mildly reduced LV function, and the presence of
viability does not exclude subendocardial infarction [9,10]. As far
as we are aware, the sensitivity of these techniques for detecting
chronic MI has not been tested. Moreover, there is a paucity of
data from multicenter trials on the sensitivity of imaging
approaches for the detection of MI, in either the acute or the
chronic setting [36]. Recently, results from an international,
multicenter trial evaluating DE-CMR for the detection of MI have
been reported [36]. In this trial, the sensitivity of DE-CMR was
tested in acute and chronic, and Q-wave and non-Q-wave MI
patients. With appropriate contrast doses (0.2 mmol/kg or higher),
DE-CMR was highly sensitive for the detection of acute and
chronic Q-wave MI (99% and 98% respectively), and acute non-
Q-wave MI (91%). The sensitivity was lowest in chronic non-Q-
wave MI at 79%, likely reflecting the small mean infarct size in this
cohort (6.8% of LV mass). Hence, while DE-CMR may be highly
sensitive for detecting MI overall, identifying chronic non-Q-wave
MI is challenging, which directly relates to the difficulty in
diagnosing unrecognized non-Q-wave MI. The implication for the
current study is that while 50 patients with non-Q-wave UMI were
identified, this number may represent only 79% of the total
number of patients with non-Q-wave UMI, and perhaps as many
as 13 (21%) were not diagnosed.
One important prior study has examined the association of
unrecognized myocardial scarring by DE-CMR and prognosis
[37]. Kwong et al. reported that in a cohort of 195 patients, those
with myocardial scarring had a more than 7-fold increased risk for
major adverse cardiac events over those without [37]. This finding
is consistent with the results of the current investigation, although
Kwong et al. reported on all patients with UMI, and those with
non-Q-wave UMI were not specifically investigated (e.g., clinical
characteristics, predictors, angiographic features, etc.). Addition-
ally, there appear to be notable differences in the two study
populations. First, considerably more patients had UMI by DE-
CMR than by ECG in the current study (62 versus 15, ratio 4.1)
than in the study by Kwong et al. (44 versus 25, ratio 1.8),
despite using the same Minnesota Code criteria for significant Q-
waves. Second, when Q-waves were present, Kwong et al.
reported that only 28% of patients had evidence of MI by DE-
CMR, leading to a surprisingly high false positive rate of 72% for
12-lead electrocardiography. In contrast, in the current study,
most patients with Q-waves (80%) demonstrated infarction by
DE-CMR, and the false positive rate for electrocardiography was
far smaller (20%). Third, cardiac mortality was quite high in the
study by Kwong et al., at 6.6% per year overall and 22% per
year in UMI patients (estimated from the reported hazard ratio).
In comparison, the cardiac mortality that we observed was 2.9%
per year overall and 6.9% per year in UMI patients. Hence, in
the population studied by Kwong et al., cardiac mortality in
those with UMI was over 3-fold higher. One potential
explanation for these disparities may relate to how the
participants were initially identified. Specifically, in the study
by Kwong et al., all patients were referred for a clinically ordered
CMR examination—a comprehensive and relatively uncommon
test in comparison with echocardiography and radionuclide
imaging. The cohort in which CMR is ordered may not be
representative of those undergoing a standard noninvasive
evaluation, and may include more patients with unusual clinical
Figure 3. Kaplan–Meier estimates of survival (A) and cardiac
survival (B) in patients with unrecognized non-Q-wave MI (blue
line) and without MI (red line). Overall and cardiac survival in
patients with non-Q-wave UMI was significantly reduced in comparison
to patients without MI (p,0.0001 for both). The annual mortality in
patients with non-Q-wave MI was 15-fold higher than that in patients
without MI (10.8% per year versus 0.8% per year, respectively).
doi:10.1371/journal.pmed.1000057.g003
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study by Kwong et al., subsequent management decisions (e.g.,
whether or not to perform diagnostic cardiac catheterization or
coronary revascularization) were in part dependent on the CMR
results. In contradistinction, in the current study, participants
were prospectively enrolled to undergo CMR only for the
purpose of research, and clinical decisions were made without
knowledge of the CMR findings.
The presence of non-Q-wave UMI was the strongest
independent predictor of mortality in the current study. Patients
with non-Q-wave UMI were older, more often diabetic, and had
a higher Framingham risk than patients without MI. Not
surprisingly, coronary atherosclerosis was extensive; multivessel
disease occurred in 86% of non-Q-wave UMI patients. Hence,
the poor prognosis associated with non-Q-wave UMI may relate
to an abundance of clinical features that are associated with
adverse outcomes. These features are also typically found in
patients with clinically overt (recognized) non-Q-wave MI [32],
who have poor outcomes—similar to or worse than those with
overt Q-wave MI when including late mortality [32]. Thus,
despite having different clinical presentations, patients with
unrecognized non-Q-wave MI appear to share many similarities
with patients presenting with overt non-Q-wave MI, in terms of
both advanced atherosclerosis and poor prognosis. However,
since the infarct was not diagnosed clinically, the poor prognosis
observed in patients with unrecognized non-Q-wave MI may
also be attributable in part to the absence of appropriate therapy
for secondary prevention.
Limitations
Beyond the presence of MI, infarct size may provide additional
prognostic information in that larger infarcts are more frequently
associated with ventricular tachyarrhythmias and sudden cardiac
death [38,39]. In the current study, the fit of the multivariable Cox
regression model was not improved by substitution of infarct size for
infarct presence/absence. However, this finding may be related to
the small number of events in the study rather than a lack of
incremental value for infarct size. Other studies have indicated that
scarring in a non-CAD-type pattern, as occasionally found in
nonischemic dilated cardiomyopathy, may also have prognostic
importance [24]. In the current study, only nine patients had
scarring in a non-CAD-type pattern, and none had events. One of
the main aims of our investigation was to directly relate the presence
of UMI with the extent and severity of coronary atherosclerosis.
Accordingly, patients scheduled for X-ray coronary angiography
were prospectively enrolled, and symptoms such as chest pain (62%)
and dyspnea (30%) were fairly common. Thus, our findings may not
be applicable to cohorts that are entirely asymptomatic. However,
we note that in large population surveys such as the Framingham
HeartStudy,symptomswerepresentinnearly50%ofpatientsfound
tohaveQ-wave UMI[5,6].Additionally,wedonot havedata on the
number of patients who were screened, declined to participate, or
were excluded over the recruitment period. As a result, we are
unsure if our cohort is fully representative of the population referred
for angiography. However, the clinical profile of our study
participants is similar to that of large population studies in which
patients without prior history of MI underwent coronary angiogra-
Table 3. Predictors of all-cause mortality.
Variables Univariable Multivariable
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value
Baseline characteristics
Age 1.02 (0.98–1.07) 0.32
Male 0.7 (0.2–1.8) 0.41
Hypertension 3.2 (0.7–14.1) 0.13
Hypercholesterolemia 0.9 (0.3–2.5) 0.85
Cigarette smoking 1.8 (0.6–4.9) 0.29
Diabetes mellitus 1.9 (0.7–5.2) 0.23
Family history of CAD 0.6 (0.2–2.0) 0.41
Number of risk factors 1.4 (0.8–2.2) 0.22
Typical angina 0.99 (0.3–2.9) 0.98
Atypical angina 0.4 (0.1–1.7) 0.38
Dyspnea 1.9 (0.7–5.2) 0.22
NYHA class 1.7 (1.02–2.7) 0.04
Framingham risk 1.02 (0.98–1.05) 0.43
CINE CMR
LVEF 0.97 (0.94–0.99) 0.004 0.97 (0.95–0.99)
a 0.04
a
End diastolic volume 1.0 (0.98–1.01) 0.56
End systolic volume 1.0 (0.99–1.01) 0.50
DE-CMR
Non-Q-wave UMI 14.1 (3.2–62.7) 0.0005 11.4 (2.5–51.1)
a 0.002
a
Revascularization during the follow-up period 2.5 (0.9–7.1) 0.09
aAfter adjustment for revascularization during the follow-up period, the hazard ratio for the presence of non-Q-wave UMI was 9.9 (95% CI 2.0–48.2), p=0.005. The
hazard ratio of LVEF was 0.97 (95% CI 0.94–0.99), p=0.04.
doi:10.1371/journal.pmed.1000057.t003
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representative of this specific population, which encompasses
approximately one-third to one-half of all patients referred for
invasive coronary angiography [40,41].
Summary
In patients with suspected coronary disease, the prevalence of
non-Q-wave as compared with Q-wave UMI was more than 3-
fold higher and was relatively common, occurring in over 25% of
the study cohort. Patients with non-Q-wave UMI frequently had
extensive coronary atherosclerosis and had more than a 11-fold
higher risk of death than those without MI. Given the aging
population and the increasing prevalence of diabetes, the ability to
identify unrecognized MI may have important implications for
individual patients and for public health policy recommendations,
However, it remains untested if early diagnosis with appropriate
MI treatment alters prognosis. Thus, clinical trials are needed to
test this strategy, and then, depending on the findings, guidelines
could be formulated for CMR referral.
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Background. Coronary artery disease (CAD; also called
coronary heart disease) is the leading cause of death among
adults in developed countries. In the USA alone, it kills nearly
half a million people every year. CAD is caused by narrowing
of the coronary arteries, the blood vessels that supply the
heart with oxygen and nutrients. With age, fatty deposits
(atherosclerotic plaques) coat the walls of these arteries and
restrict the heart’s blood supply, which causes the
characteristic symptoms of CAD—angina (chest pains that
are usually relieved by rest) and shortness of breath. In
addition, if a plaque breaks off the wall of a coronary artery, it
can completely block that artery and kill part of the heart,
which causes a potentially fatal heart attack (doctors call this
a myocardial infarction or MI). Heart attacks are often
characterized by long-lasting chest pain that is not relieved
by rest. Risk factors for CAD include smoking, high blood
pressure, high blood levels of cholesterol (a type of fat), and
being overweight. Treatments for the condition include
lifestyle changes (for example, losing weight), and
medications that lower blood pressure and blood
cholesterol. The narrowed arteries can also be widened
using a device called a stent or surgically bypassed.
Why Was This Study Done? Not everyone who has a
heart attack has chest pain. In fact, some studies suggest that
40–60% of MIs have no obvious symptoms. It is important,
however, that these ‘‘unrecognized’’ MIs (UMIs) are diagnosed
because they have death rates similar to those of MIs with
clinical symptoms and need to be treated in a similar way.
Traditionally, UMIs have been diagnosed using an
electrocardiogram (ECG). When the heart beats, it generates
small electric waves that can be picked up by electrodes
attached to the skin. The pattern of these waves (the ECG)
provides information about the heart’s health. Alterations in
the ECG, leading to so-called Q-waves, indicate that a UMI has
occurred some time previously. However, not all UMIs result in
Q-waves. In this study, the researchers use a recently
developed technique—delayed enhancement cardiovascular
magnetic resonance (DE-CMR), which can detect heart
damage even in patients whose Q-waves are absent—to
measurethe prevalence (thefraction ofapopulationthathas a
disorder) of non-Q-wave UMI. The researchers also investigate
whether non-Q-wave UMI increases the risk of death.
What Did the Researchers Do and Find? The researchers
used electrocardiography and DE-CMR to look for Q-wave
and non-Q-wave UMI, respectively, in 185 patients with
suspected CAD but no history of MI. They then followed
the patients for 2 years to discover whether a diagnosis of
non-Q-wave UMI predicted their likelihood of dying from any
cause or from a heart problem. 27% of the patients had
evidence of non-Q-wave UMI whereas only 8% had evidence
of Q-wave UMI. Patients with non-Q-wave UMI tended to
have only a small area of heart damage and, consistent with
this limited damage, their hearts pumped near-normal
volumes of blood. Examination of the patients’ arteries
with a technique called coronary angiography indicated that
the patients with widespread and/or severe CAD had a
higher prevalence of non-Q-wave UMI than those with
limited CAD. Finally, patients with non-Q-wave UMI had an
11-fold higher risk of death from any cause and a 17-fold
higher risk of death from a heart problem than patients
without UMI.
What Do These Findings Mean? These findings indicate
that non-Q-wave UMI occurs more than 3-times as often in
patients with suspected CAD than Q-wave UMI and that
patients with non-Q-wave UMI have a much greater risk of
dying than patients without MI. Thus, if all cases of UMI—
both Q-wave and non-Q-wave UMI—could be identified, it
might be possible to reduce the number of deaths among
people with CAD. However, before any recommendations
are made to include DE-CMR in the routine examination of
people with suspected CAD to achieve this aim, additional
studies must be undertaken to confirm that non-Q-wave UMI
is a common feature of CAD and to test whether the early
diagnosis of non-Q-wave UMI does extend the life
expectancy of people with CAD.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000057.
N This study is further discussed in a PLoS Medicine
Perspective by Clara Chow
N The MedlinePlus encyclopedia has pages on coronary
heart disease, heart attacks, and electrocardiograms (in
English and Spanish). MedlinePlus also provides links to
further information on all aspects of heart disease (in
English and Spanish)
N Information is available from the US National Heart Lung
and Blood Institute on coronary heart disease
N The UK National Health Service Choices website also
provides information about coronary heart disease (in
several languages).
N The Nobel Foundation provides an interactive electrocar-
diogram game
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